Fig. 6

EGOT/ITPR1 expression is associated with a favorable prognosis and enhances paclitaxel sensitivity in human cancer. a, b Kaplan-Meier analyses of the relationships between EGOT expression and OS (a) or RFS (b) in breast cancer patients in the HMUCC cohort. c, d Kaplan-Meier analyses of the relationships between EGOT expression and OS among 33 cancer types in TCGA (c) and ICGC cohorts (d). e, f Kaplan-Meier analyses of the relationships between EGOT expression and OS (e) or RFS (f) in breast cancer patients treated with paclitaxel in the HMUCC cohort. g Kaplan-Meier analyses of the relationship between EGOT expression and OS in breast cancer patients treated with paclitaxel in the TCGA cohort. h The correlations between EGOT expression and ITPR1 mRNA expression were measured in 15 breast cancer patients treated with paclitaxel-containing adjuvant chemotherapy regimens (left). EGOT and ITPR1 levels (normalized to GAPDH) were subjected to Pearson’s correlation analysis. Correlations between EGOT expression and a pathological response were determined by the chi-square test (right). A complete pathological response is denoted by CR, while a partial response is denoted by PR. The median expression level was used as the cut-off value. Patients with EGOT expression values below the 50th percentile were classified as EGOT-Low. Patients with EGOT expression values above the 50th percentile were classified as EGOT-High